http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2571707-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_11b3a64311ef238a0672df3c2aa5e50f |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-00 |
| filingDate | 2014-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9cddfda4dc4bb71bd82d59cd456908b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9e964853df2901cd8469861f9d9892d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d42e24f4f91356cdf45e6a7ef5b36955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_303f59d0200ab1c86aeaf23cfe2899e0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d47c563bde452836fb81f9d2b1f28a9e |
| publicationDate | 2015-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2571707-C1 |
| titleOfInvention | Method for optimising selecting antianginal therapy in ischemic heart disease and microvascular angina |
| abstract | FIELD: medicine. n SUBSTANCE: LDF and capillaroscopy initial parameters are determined. Recommended antianginal preparations are administered one by one for 3 days. Each following preparations is administered 5 excretion half-lives after the previous one, and each course is followed by determining the LDF parameters. That involves assessing: vascular reaction of skin microcirculation, functional health of tonus-forming mechanisms of blood flow modulation: endothelial - Ae, neurogenic - An and myogenic - Am, respiratory blood flow variations - Av, pulse blood flow variations - As, as well as the capillaroscopy parameters that is a pericapillary area - PA. The LDF and capillaroscopy (PA) initial parameters are compared to those obtained after the preparations tested are administered, and the most optimum preparation which makes the parameters Ae, An, Am and As normalise with Av≤0.08, PA = 105±15 is selected for a continuous therapy. n EFFECT: method enables providing higher therapeutic effectiveness and prevents disease recurrences in the patients with ischemic heart disease and microvascular angina. n 3 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2695767-C1 |
| priorityDate | 2014-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 25.